

ROBERT J DOLE VA MEDICAL CENTER
Facility NIOSH List of Hazardous Medications

Annual Review Completion Date	December 15, 2021
Review Completed by: (Name/Title)	Steven Williams, RPh Facility Compounded Sterile Products Program Manager
Signature:	

Summary of Changes:

Additions to List:

baricitinib
belantamab mafodotin
fam-trastuzumab deruxtecan
inotuzumab ozofoamicin
lurbinectedin
regorafenib
romidepsin
trabectedin

Removals From List:

bevacizumab
cetuximab
darvalumab
elotuzumab
ipilimumab
natalizumab
panitumumab
pembrolizumab
pertuzumab
ramucivumab
rasburicase
rituximab
trastuzumab

ROBERT J DOLE VA MEDICAL CENTER
Facility NIOSH List of Hazardous Medications

The drugs in [Table 1](#) (Below) meet one or more of the NIOSH criteria for a hazardous drug. In addition to many of these drugs being cytotoxic, the majority are hazardous to males or females who are actively trying to conceive, women who are pregnant or may become pregnant, and women who are breast feeding, because they may be present in breast milk. These drugs represent an occupational hazard to healthcare workers and should always be handled with use of recommended engineering controls and personal protective equipment (PPE), regardless of their formulation (IV [intravenous], SC [subcutaneous], topical, tablet, or capsule). Unopened, intact tablets and capsules may not pose the same degree of occupational exposure risk as injectable drugs, which usually require extensive preparation. Cutting, crushing, or otherwise manipulating tablets and capsules will increase the risk of exposure to workers. The manufacturer's safe-handling guidance (MSHG) is typically in Section 16 of the DPI. See [Table 5](#) for safe-handling recommendations.

Abbreviations and footnotes. AHFS = American Hospital Formulary Service; MRHD = maximum recommended human dose.

National Toxicology Program classifications (<http://ntp.niehs.nih.gov/pubhealth/roc/index.html>): **Known To Be Human Carcinogens; ***Reasonably Anticipated To Be Human Carcinogens.

†International Agency for Research on Cancer (www.iarc.fr): Group 1, Carcinogenic to Humans; Group 2A, Probably Carcinogenic to Humans; Group 2B, Possibly Carcinogenic to Humans.

‡BCG, although classified as a vaccine, is used in the treatment of certain cancers. BCG should be prepared with aseptic techniques. To avoid cross-contamination, parenteral drugs should not be prepared in areas where BCG has been prepared. A separate area for the preparation of BCG suspension is recommended. All equipment, supplies, and receptacles in contact with BCG should be handled and disposed of as biohazardous. If preparation cannot be performed in a containment device, then respiratory protection, gloves, and a gown should be worn to avoid inhalation or contact with BCG organisms.

Table	<i>listed in Niosh black (not listed Niosh yellow)</i>	VA Class	Dosage Form	Handling	Probs	Risk Assessment Link
1	Abiraterone (page 9)	AN500 ANTINEOPLASTIC HORMONES	Tablet	Oral	FDA Pregnancy Category X	Abiraterone Tablet.docx
1	Ado-Trastuzumab Emtansine	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	Monoclonal antibody conjugated to metransine	Meets all <USP 800> and NIOSH requirements
1	Anastrozole (page 10)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category X	Anastrozole Tablet.docx
1	Arsenic Trioxide (page 10)	AN900 ANTINEOPLASTIC OTHER	Ampule	IV infusion	Avoid Pregnancy During & 3 Months after Tx BW: RA-APL, QT Prolongation	Meets all <USP 800> and NIOSH requirements
1	Axitinib (page 10)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy category D	Axitinib Tablet.docx
1	Azacitidine (page 10)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Vial	IV infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Bacillus Calmette Guerin BCG live	AN900 ANTINEOPLASTIC OTHER	Vial	Intravesical	FDA Pregnancy Category C	Meets all <USP 800> and NIOSH requirements
1	BELANTAMAB MAFODOTIN	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion		Meets all <USP 800> and NIOSH requirements
1	Bendamustine (page 10)	AN100 ANTINEOPLASTICS, ALKYLATING AGENTS	Vial	IV Infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Bexarotene (page 10)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	FDA Pregnancy Category X	Bexarotene Capsule.docx
1	Bexarotene (page 10)	AN900 ANTINEOPLASTIC OTHER	Top Gel	Topical	FDA Pregnancy Category X	Bexarotene Topical Gel.docx
1	Bicalutamide (page 10)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category X	Bicalutamide Tablet.docx
1	Bleomycin (page 10)	AN200 ANTINEOPLASTIC ANTIBIOTICS	Vial	IV infusion	FDA Pregnancy Category D BW: Pulmonary Toxicity, Idiosyncratic Rxn	Meets all <USP 800> and NIOSH requirements
1	Bortezomib (page 10)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Bosutinib (page 11)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category D	Bosutinib Tablet.docx
1	Busulfan (page 11)	AN100 ANTINEOPLASTICS, ALKYLATING AGENTS	Tablet	Oral	FDA Pregnancy Category D	Busulfan Tablet.docx
1	Cabazitaxel (page 11)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Cabozantinib (page 11)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category D	Cabozantinib Capsule.docx
1	Capecitabine (page 11)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Tablet	Oral	FDA Pregnancy Category D	Capecitabine Tablet.docx
1	Carboplatin (page 11)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Carfilzomib (page 11)	AN900 ANTINEOPLASTIC OTHER	Vial	IV infusion	FDA Pregnancy Category D, Contraception During & 3 Months after Tx	Meets all <USP 800> and NIOSH requirements
1	Carmustine (page 11)	AN100 ANTINEOPLASTICS, ALKYLATING AGENTS	Vial	IV infusion	GROUP 2A	Meets all <USP 800> and NIOSH requirements
1	Chlorambucil (page 11)	AN100 ANTINEOPLASTICS, ALKYLATING AGENTS	Tablet	Oral	FDA Pregnancy Category D; Carcinogen GROUP 1	Chlorambucil Tablet.docx
1	Cisplatin (page 11)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D; Carcinogen GROUP 2A	Meets all <USP 800> and NIOSH requirements
1	Cladribine (page 11)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Vial	IV infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Cyclophosphamide (page 12)	AN100 ANTINEOPLASTICS, ALKYLATING AGENTS	Capsule	Oral	FDA Pregnancy Category D; Carcinogen GROUP 1	Cyclophosphamide Capsule.docx
1	Cyclophosphamide (page 12)	AN100 ANTINEOPLASTICS, ALKYLATING AGENTS	Vial	IV Infusion	FDA Pregnancy Category D; Carcinogen GROUP 1	Meets all <USP 800> and NIOSH requirements
1	Cytarabine (page 12)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Vial	IV Infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Dabrafenib (page 12)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	FDA Pregnancy Category D, Contraception During & 2 Weeks after Tx	Dabrafenib Capsule.docx
1	Dacarbazine (page 12)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category C	Meets all <USP 800> and NIOSH requirements
1	Dactinomycin (page 12)	AN200 ANTINEOPLASTIC ANTIBIOTICS	Vial	IV infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Dasatinib (page 12)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	manufacturer, personnel who are pregnant should avoid exposure to crushed or broken	Dasatinib Tablet.docx
1	Daunorubicin (page 12)	AN200 ANTINEOPLASTIC ANTIBIOTICS	Vial	IV Infusion	FDA Pregnancy Category D; Carcinogen GROUP 2B	Meets all <USP 800> and NIOSH requirements

ROBERT J DOLE VA MEDICAL CENTER
Facility NIOSH List of Hazardous Medications

Table	<i>listed in Niosh black (not listed Niosh yellow)</i>	VA Class	Dosage Form	Handling	Probs	Risk Assessment Link
1	Decitabine (page 12)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Degarelix (page 12)	AN500 ANTINEOPLASTIC HORMONES	Vial	SC	FDA Pregnancy Category X	Degarelix.docx
1	Docetaxel (page 12)	AN900 ANTINEOPLASTIC OTHER	Vial	IV infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Doxorubicin (page 12)	AN200 ANTINEOPLASTIC ANTIBIOTICS	Vial	IV Infusion	FDA Pregnancy Category D; Carcinogen GROUP 2A	Meets all <USP 800> and NIOSH requirements
1	ENFORTUMAB VEDOTIN (Padcev)		Vial	IV Infusion		Meets all <USP 800> and NIOSH requirements
1	Enzalutamide (page 12)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	FDA Pregnancy Category X	Enzalutamide Capsule.docx
1	Epirubicin (page 13)	AN200 ANTINEOPLASTIC ANTIBIOTICS	Vial	IV Infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Erlotinib (page 13)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category D	Erlotinib Tablet.docx
1	Estramustine (page 13)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	FDA Pregnancy Category X	Estramustine Capsule.docx
1	Etoposide (page 13)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D; Carcinogen GROUP 1	Meets all <USP 800> and NIOSH requirements
1	Etoposide (page 13)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	FDA Pregnancy Category D; Carcinogen GROUP 1	Etoposide Capsule.docx
1	Everolimus (page 13)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category D	Everolimus Tablet.docx
1	Exemestane (page 13)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category X	Exemestane Tablet.docx
1	Fam-Trastuzumab Deruxtecan	AN900 ANTINEOPLASTIC OTHER	Vial	IV infusion	BW: Cardiomyopathy, Infusion Rxn, Pulmonary toxicity, Pregnancy Embryo-Fetal toxicity	Meets all <USP 800> and NIOSH requirements
1	Fludarabine (page 13)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Vial	IV Infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Fluorouracil (page 13)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Vial	IV infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Fluorouracil (page 13)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Topical Cream Topical Solution	Topical	FDA Pregnancy Category D	Fluorouracil Topical.docx
1	Flutamide (page 13)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	FDA Pregnancy Category D	Flutamide Capsule.docx
1	Fulvestrant (page 13)	AN500 ANTINEOPLASTIC HORMONES	Syringe	IM	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Gemcitabine (page 13)	AN900 ANTINEOPLASTIC OTHER	Vial	IV infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Gemtuzumab ozogamicin (page 13)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Goserelin (page 13)	AN500 ANTINEOPLASTIC HORMONES	Syringe	Implant	FDA Pregnancy Category X	Goserelin Injection.docx
1	Hydroxyurea (page 14)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Capsule	Oral	FDA Pregnancy Category D	Hydroxyurea Capsule.docx
1	Ifosfamide (page 14)	AN100 ANTINEOPLASTICS, ALKYLATING AGENTS	Vial	IV Infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Imatinib (page 14)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category D	ImatinibTablet.docx
1	INOTUZUMAB OZOGAMICIN	AN900 ANTINEOPLASTIC OTHER	Vial	IV infusion		Meets all <USP 800> and NIOSH requirements
1	Irinotecan (page 14)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Ixabepilone (page 14)	AN900 ANTINEOPLASTIC OTHER	Vial	IV infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Ixazomib (page 14)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	Avoid Pregnancy During & 3 Months after Tx	Ixazomib Capsule.docx
1	Letrozole (page 14)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category X	Letrozole Tablet.docx
1	Leuprolide (page 14)	AN500 ANTINEOPLASTIC HORMONES	Vial	SC	FDA Pregnancy Category X	Leuprolide.docx
1	Lomustine (page 14)	AN100 ANTINEOPLASTICS, ALKYLATING AGENTS	Capsule	Oral	FDA Pregnancy Category D; Carcinogen GROUP 2A	Lomustine Capsule.docx
1	Lurbinectedin	AN900 ANTINEOPLASTIC OTHER	Vial	IV infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Megestrol (page 14)	HS800 PROGESTINS	Tablet	Oral	FDA Pregnancy Category D, X	Megestrol Tablet.docx
1	Megestrol (page 14)	HS800 PROGESTINS	Liquid	Oral	FDA Pregnancy Category D, X	Megestrol Oral Solution.docx
1	Melphalan (page 14)	AN100 ANTINEOPLASTICS, ALKYLATING AGENTS	Vial	IV infusion	FDA Pregnancy Category D; Carcinogen GROUP 1	Meets all <USP 800> and NIOSH requirements
1	Melphalan (page 14)	AN100 ANTINEOPLASTICS, ALKYLATING AGENTS	Tablet	Oral	FDA Pregnancy Category D; Carcinogen GROUP 1	Melphalan Tablet.docx
1	Mercaptopurine (page 15)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Tablet	Oral	FDA Pregnancy Category D	Mercaptopurine Tablet.docx
1	Methotrexate (page 15)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Tablet	Oral	FDA Pregnancy Category X	Methotrexate Oral.docx
1	Methotrexate (page 15)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Vial	IV, SC	FDA Pregnancy Category X	Methotrexate Inj.docx
1	Mitomycin (page 15)	AN200 ANTINEOPLASTIC ANTIBIOTICS	Vial	IV Infusion	FDA Pregnancy Category D; Carcinogen GROUP 2B	Meets all <USP 800> and NIOSH requirements
1	Mitotane (page 15)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category D	Mitotane Tablet.docx
1	Nilotinib (page 15)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	FDA Pregnancy Category D	Nilotinib Capsule.docx
1	Oxaliplatin (page 15)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D BW: Hypersensitivity/Anaphylactic Reaction	Meets all <USP 800> and NIOSH requirements
1	Paclitaxel (page 15)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D BW: Hypersensitivity Reaction Bone Marrow Suppression	Meets all <USP 800> and NIOSH requirements
1	Pazopanib (page 15)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category D BW: Hepatotoxicity	Pazopanib Tablet.docx
1	Pemetrexed (page 15)	AN300 ANTINEOPLASTICS,ANTIMETABOLITES	Vial	IV infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements

ROBERT J DOLE VA MEDICAL CENTER
Facility NIOSH List of Hazardous Medications

Table	<i>listed in Niosh black (not listed Niosh yellow)</i>	VA Class	Dosage Form	Handling	Probs	Risk Assessment Link
1	Pertuzumab (page 15)	AN900 ANTINEOPLASTIC OTHER	Vial	IV infusion	FDA Pregnancy Category D BW: Cardiotoxicity, Pregnancy embryo-fetal Death, Birth Defects	Meets all <USP 800> and NIOSH requirements
1	Procarbazine (page 16)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	FDA Pregnancy Category D GROUP 2A	Procarbazine Capsule.docx
1	Romidepsin	AN900 ANTINEOPLASTIC OTHER	Vial	IV infusion	FDA Pregnancy Category D	Meets all <USP 800> and NIOSH requirements
1	Sorafenib (page 16)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category D	Sorafenib Tablet.docx
1	Sunitinib (page 16)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	Hepatotoxicity	Sunitinib Capsule.docx
1	Tamoxifen (page 16)	AN500 ANTINEOPLASTIC HORMONES	Tablet	Oral	FDA Pregnancy Category D GROUP1 BW: Ductal, Uterine Carcinomas, Stroke & Pulmonary Embolism	Tamoxifen Tablet.docx
1	Temozolomide (page 16)	AN100 ANTINEOPLASTICS, ALKYLATING AGENTS	Capsule	Oral	FDA Pregnancy Category D	Temozolamide Capsule.docx
1	Topotecan (page 17)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	FDA Pregnancy Category D BW: Bone marrow suppression	Topotecan Capsule.docx
1	Topotecan (page 17)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D BW: Bone marrow suppression	Meets all <USP 800> and NIOSH requirements
1	TRABECTEDIN (Yondelis)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion		Meets all <USP 800> and NIOSH requirements
1	Vemurafenib (page 17)	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	FDA Pregnancy Category D Avoid Pregnancy During & 2 Weeks after Tx	Vemurafenib Tablet.docx
1	VENETOCLAX	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	Avoid Pregnancy During & 30 Days after Tx	Venetoclax Tablet.docx
1	Vinblastine (page 17)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D BW: Extravasation	Meets all <USP 800> and NIOSH requirements
1	Vincristine (page 17)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Push	FDA Pregnancy Category D BW: Extravasation	Meets all <USP 800> and NIOSH requirements
1	Vinorelbine (page 17)	AN900 ANTINEOPLASTIC OTHER	Vial	IV Infusion	FDA Pregnancy Category D BW: Extravasation	Meets all <USP 800> and NIOSH requirements

ROBERT J DOLE VA MEDICAL CENTER
Facility NIOSH List of Hazardous Medications

Table	<i>listed in Niosh black (not listed Niosh yellow)</i>	VA Class	Dosage Form	Handling	Probs	Risk Assessment Link
-------	--	----------	-------------	----------	-------	----------------------

The drugs in Table 2 (Below) meet one or more of the NIOSH criteria for a hazardous drug. Some of these drugs may represent an occupational hazard to males or females who are actively trying to conceive, women who are pregnant or may become pregnant, and women who are breast feeding, because they may be present in breast milk.

Unopened, intact tablets and capsules may not pose the same degree of occupational exposure risk as injectable drugs, which usually require extensive preparation. Cutting, crushing, or otherwise manipulating tablets and capsules will increase the risk of exposure to workers. The manufacturer's safe-handling guidance (MSHG) is typically in Section 16 of the DPI. See Table 5 for safe-handling recommendations.

Abbreviations and footnotes. AHFS = American Hospital Formulary Service; MRHD = maximum recommended human dose.

*Drugs in blue font meet one or more criteria for a hazardous drug and also pose a potential reproductive hazard.

National Toxicology Program (<http://ntp.niehs.nih.gov/pubhealth/roc/index.html>): **Known To Be Human Carcinogens; ***Reasonably Anticipated To Be Human Carcinogens.

†International Agency for Research on Cancer (www.iarc.fr): Group 1, Carcinogenic to Humans; Group 2A, Probably Carcinogenic to Humans; Group 2B, Possibly Carcinogenic to Humans.

Table	<i>listed in Niosh black (not listed Niosh yellow)</i>	VA Class	Dosage Form	Handling	Probs	Risk Assessment Link
2	Abacavir (page 19)	AM800 ANTIVIRALS	Tablet	Oral	FDA Pregnancy category C	Abacavir Tablet.docx
2	Azathioprine (page 20)	IM600 IMMUNE SUPPRESSANTS	Tablet	Oral	FDA Pregnancy Category D; Carcinogen GROUP 1	Azathioprine Tablets.docx
2	Baricitinib	MS190 ANTIRHEUMATICS OTHER	Tablet	Oral	FDA Pregnancy Category X; Bone marrow, lymphoid toxicity	Baricitinib Tablet.docx
2	Carbamazepine (page 19)	CN400 ANTICONVULSANTS	Tablet	Oral	FDA Pregnancy category D BW: Serious dermatologic Rxn, Aplastic anemia & Agranulocytosis	Carbamazepine Tablet, Capsule.docx
2	Carbamazepine (page 19)	CN400 ANTICONVULSANTS	Oral Suspension	Oral	FDA Pregnancy category D BW: Serious dermatologic Rxn, Aplastic anemia & Agranulocytosis	Carbamazepine Suspension.docx
2	Cidofovir (page 20)	AM800 ANTIVIRALS	Vial	IV infusion	FDA Pregnancy category C BW: Nephrotoxicity, Neutropenia, Carcinogenic/Teratogenic	Cidofovir Solution for Injection.docx
2	Cyclosporine (page 20)	IM600 IMMUNE SUPPRESSANTS	Capsule	Oral	FDA Pregnancy category C GROUP1 BW: Infection Susceptibility, Hypertension & Nephrotoxicity	Cyclosporine Capsule.docx
2	Cyclosporine (page 20)	IM600 IMMUNE SUPPRESSANTS	Oral Solution	Oral	FDA Pregnancy category C GROUP1 BW: Infection Susceptibility, Hypertension & Nephrotoxicity	Cyclosporine Oral Solution.docx
2	Cyclosporine (page 20)	IM600 IMMUNE SUPPRESSANTS	Vial	IV Infusion	FDA Pregnancy category C GROUP1 BW: Infection Susceptibility, Hypertension & Nephrotoxicity	Cyclosporine Injection.docx
2	Cyclosporine (page 20)	IM600 IMMUNE SUPPRESSANTS	Eye Drop	Ophthalmic	FDA Pregnancy category C GROUP1 BW: Infection Susceptibility, Hypertension & Nephrotoxicity	Cyclosporine Ophthalmic Drops.docx
2	Dexrazoxane (page 20)	AN700 PROTECTIVE AGENTS	Vial	IV infusion	FDA Pregnancy Category C	Dexrazoxane Powder for Injection.docx
2	Divalproex (page 20)	CN400 ANTICONVULSANTS	Tablet	Oral	FDA Pregnancy category D BW: Hepatotoxicity, Mitochondrial disease, Fetal risk, Pancreatitis	Divalproex Oral Tablet or Capsule.docx
2	Entecavir (page 20)	AM800 ANTIVIRALS	Tablet	Oral	FDA Pregnancy category C BW: Severe acute exacerbations Hep B., Lactic acidosis & Hepatomegaly	Entecavir Tablet.docx
2	Estradiol (page 21)	HS300 ESTROGENS	Tablet	Oral	FDA Pregnancy category X BW: Endometrial cancer, Cardiovascular disorders, W/ Progestins Breast cancer	Estradiol Tablet.docx
2	Estradiol (page 21)	HS300 ESTROGENS	Vial	Inj	FDA Pregnancy category X BW: Endometrial cancer, Cardiovascular disorders, W/ Progestins Breast cancer	Estradiol Injection.docx
2	Estradiol (page 21)	HS300 ESTROGENS	Gel	Topical	FDA Pregnancy category X BW: Endometrial cancer, Cardiovascular disorders, W/ Progestins Breast cancer	Estradiol Gel.docx
2	Estrogen / Progesterone Combinations (page 21)	HS300 ESTROGENS	Tablet	Oral	FDA Pregnancy category X BW: Endometrial cancer, Cardiovascular disorders, W/ Progestins Breast cancer	Estradiol & Progesterone Combination Tablet.docx
2	Estrogens Conjugated (page 21)	HS300 ESTROGENS	Tablet	Oral	FDA Pregnancy category X BW: Endometrial cancer, Cardiovascular disorders, W/ Progestins Breast cancer	Estrogens Conjugated Tablet.docx
2	Estrogens Conjugated (page 21)	HS300 ESTROGENS	Vial	Inj	FDA Pregnancy category X BW: Endometrial cancer, Cardiovascular disorders, W/ Progestins Breast cancer	Estrogens Conjugated Injection.docx

ROBERT J DOLE VA MEDICAL CENTER
Facility NIOSH List of Hazardous Medications

Table	<i>listed in Niosh black (not listed Niosh yellow)</i>	VA Class	Dosage Form	Handling	Probs	Risk Assessment Link
2	Estrogens Conjugated (page 21)	HS300 ESTROGENS	Cream	Topical	FDA Pregnancy category X BW: Endometrial cancer, Cardiovascular disorders, W/ Progestins Breast cancer	Estrogens Conjugated Cream.docx
2	Estrogens, Esterified (page 21)	HS300 ESTROGENS	Tablet	Oral	cancer, Cardiovascular disorders, W/ Progestins Breast cancer	Estrogens, Esterified Tablet.docx
2	Estropipate (page 21)	HS300 ESTROGENS	Tablet	Oral	FDA Pregnancy category X BW: Endometrial cancer, Cardiovascular disorders, Breast cancer, Dementia	Estropipate Tablet.docx
2	Fingolimod (page 21)	MS900 MUSCULOSKELETAL AGENTS,OTHER	Capsule	Oral	FDA Pregnancy category C	Fingolimod Capsule.docx
2	Fosphenytoin (page 21)	CN400 ANTICONVULSANTS	Vial	IV Infusion	FDA Pregnancy category D BW: Cardiovascular risk W/ Rapid infusion rates	Fosphenytoin Injection.docx
2	Ganciclovir (page 22)	AM800 ANTIVIRALS	Gel	Ophthalmic	FDA Pregnancy Category C	Ganciclovir Ophthalmic Gel.docx
2	Leflunomide (page 22)	MS190 ANTIRHEUMATICS OTHER	Tablet	Oral	FDA Pregnancy Category X BW: Hepatotoxicity, Embryo-fetal toxicity	Leflunomide.docx
2	Lenalidomide (page 22)	IM900 IMMUNOLOGICAL AGENTS OTHER	Capsule	Oral	FDA Pregnancy category X BW: Fetal risk, Hematologic toxicity, Venous & Arterial thromboembolism	Lenalidomide.docx
2	Medroxyprogesterone acetate (page 22)	HS800 PROGESTINS	Tablet	Oral	FDA Pregnancy category X GROUP 2B BW: Cardiovascular disorders, Breast Cancer, Dementia	Medroxyprogesterone acetate tab.docx
2	Medroxyprogesterone acetate (page 22)	HS800 PROGESTINS	Vial	IM	FDA Pregnancy category X GROUP 2B BW: Cardiovascular disorders, Breast Cancer, Dementia	Medroxyprogesterone acetate inj.docx
2	Methimazole (page 22)	HS852 ANTITHYROID AGENTS	Tablet	Oral	FDA Pregnancy category D	Methimazole.docx
2	METHOXSALEN	DE810 ANTIPSORIATICS,SYSTEMIC	Capsule	Oral	FDA Pregnancy Category C BW: Providers Special Competence to Dx & Tx Psoriasis & Vitiligo	Methoxsalen Capsule.docx
2	Mycophenic acid (page 23)	IM600 IMMUNE SUPPRESSANTS	Tablet	Oral	FDA Pregnancy Category D BW: Genotoxic & Lymphomas	Mycophenolic acid.docx
2	Mycophenolate Mofetil (page 23)	IM600 IMMUNE SUPPRESSANTS	Tablet or Capsule	Oral	FDA Pregnancy Category D BW: Fetal Toxicity & Congenital Malformations	Mycophenolate mofetil tab or cap.docx
2	Mycophenolate Mofetil (page 23)	IM600 IMMUNE SUPPRESSANTS	Vial	Injection	FDA Pregnancy Category D BW: Fetal Toxicity & Congenital Malformations	Mycophenolate mofetil injection.docx
2	Mycophenolate Mofetil (page 23)	IM600 IMMUNE SUPPRESSANTS	Oral Suspension	Oral	FDA Pregnancy Category D BW: Fetal Toxicity & Congenital Malformations	Mycophenolate mofetil suspension.docx
2	Oxcarbazepine (page 23)	CN400 ANTICONVULSANTS	Tablet	Oral	FDA Pregnancy category C	Oxcarbazepine Tablet.docx
2	Phenoxybenzamine (page 24)	AU200 SYMPATHOLYTICS	Capsule	Oral	FDA Pregnancy category C GROUP 2B	Phenoxybenzamine Capsule.docx
2	Phenytoin (page 24)	CN400 ANTICONVULSANTS	Capsule or Tablet	Oral	FDA Pregnancy category D GROUP 2B BW: Not to exceed 50mg/minute intravenously	Phenytoin Capsule or Tablet.docx
2	Phenytoin (page 24)	CN400 ANTICONVULSANTS	Oral Suspension	Oral	FDA Pregnancy category D GROUP 2B BW: Not to exceed 50mg/minute intravenously	Phenytoin Oral Suspension.docx
2	Phenytoin (page 24)	CN400 ANTICONVULSANTS	Vial	IV Infusion	FDA Pregnancy category D GROUP 2B BW: Not to exceed 50mg/minute intravenously	Phenytoin Injection.docx
2	Progesterone (page 24)	HS800 PROGESTINS	Capsule	Oral	IARC GROUP 2B	Progesterone Capsule.docx
2	Progesterone (page 24)	HS800 PROGESTINS	Vial	Injection	IARC GROUP 2B	Progesterone Injection.docx
2	Progesterone (page 24)	HS800 PROGESTINS	Gel/Cream/VT	Topical	IARC GROUP 2B	Progesterone Vaginal Products.docx
2	Propylthiouracil (page 24)	HS852 ANTITHYROID AGENTS	Tablet	Oral	FDA Pregnancy category D BW: Hepatotoxicity, Fetal risk	Propylthiouracil.docx
2	Raloxifene (page 24)	HS900 HORMONES/SYNTHETICS/MODIFIERS	Tablet	Oral	FDA Pregnancy category X BW: Venous thromboembolism, Death from stroke	Raloxifene.docx
2	Rasagiline (page 24)	CN500 ANTIPARKINSON AGENTS	Tablet	Oral	FDA Pregnancy category C	Rasagiline.docx
2	Sirolimus (page 24)	IM600 IMMUNE SUPPRESSANTS	Tablet	Oral	FDA Pregnancy Category C BW: Immunosuppression, Liver & Lung Transplantation mortality	Sirolimus.docx
2	Spironolactone (page 25)	CV704 POTASSIUM SPARING/COMBIN DIURETICS	Tablet	Oral	FDA Pregnancy category C BW: Tumorigenicity in lab studies	Spironolactone.docx
2	Tacrolimus (page 25)	IM600 IMMUNE SUPPRESSANTS	Capsule / Oint	Oral / Topical	FDA Pregnancy Category C BW: Malignancies & Serious Infection	Tacrolimus.docx
2	Thalidomide (page 25)	IM900 IMMUNOLOGICAL AGENTS OTHER	Capsule	Oral	FDA Pregnancy category X BW: Thromboembolic events, Birth defects, Embryo-fetal death	Thalidomide.docx
2	Tofacitinib (page 25)	IM900 IMMUNOLOGICAL AGENTS OTHER	Tablet	Oral	infections, Malignancy	Tofacitinib.docx
2	Valganciclovir (page 25)	AM800 ANTIVIRALS	Tablet	Oral	FDA Pregnancy Category C BW: Hematologic & Fetal toxicity, Mutagenesis, Carcinogenesis	Valganciclovir.docx

ROBERT J DOLE VA MEDICAL CENTER
 Facility NIOSH List of Hazardous Medications

Table	<i>listed in Niosh black (not listed Niosh yellow)</i>	VA Class	Dosage Form	Handling	Probs	Risk Assessment Link
2	Zidovudine (page 25)	AM800 ANTIVIRALS	Capsule	Oral	FDA Pregnancy category C GROUP 2B BW: Hematologic toxicity, Myopathy, Lactic acidosis, Severe Hepatomegaly	Zidovudine Oral.docx
2	Zidovudine (page 25)	AM800 ANTIVIRALS	Vial	Injection	FDA Pregnancy category C GROUP 2B BW: Hematologic toxicity, Myopathy, Lactic acidosis, Severe Hepatomegaly	Zidovudine Injection.docx

ROBERT J DOLE VA MEDICAL CENTER
Facility NIOSH List of Hazardous Medications

Table	<i>listed in Niosh black (not listed Niosh yellow)</i>	VA Class	Dosage Form	Handling	Probs	Risk Assessment Link
-------	--	----------	-------------	----------	-------	----------------------

The drugs in Table 3 (Below) primarily meet the NIOSH criteria for reproductive hazards. They represent a potential occupational hazard to males or females who are actively trying to conceive, women who are pregnant or may become pregnant, and women who are breast feeding, as they may be present in breast milk. Unopened, intact tablets and capsules may not pose the same degree of occupational risk as injectable drugs that usually require extensive preparation. Cutting, crushing, or otherwise manipulating tablets and capsules will increase the risk of exposure to workers. The manufacturer's safe-handling guidance (MSHG) is typically in Section 16 of the DPI. See Table 5 for safe handling recommendations.

Table	<i>listed in Niosh black (not listed Niosh yellow)</i>	VA Class	Dosage Form	Handling	Probs	Risk Assessment Link
3	Acitretin (page 26)	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	Syndrome	Acitretin Oral Capsule.docx
3	Cabergoline (page 26)	AU900 AUTONOMIC AGENTS, OTHER	Tablet	Oral	FDA Pregnancy Category B	Cabergoline Tablet.docx
3	Clomiphene (page 26)	HS400 GONADOTROPINS	Tablet	Oral	FDA Pregnancy Category X	Clomiphene Tablet.docx
3	Clonazepam (page 26)	CN302 BENZODIAZEPINE DERIVATIVE	Tablet	Oral	FDA Pregnancy Category D BW: Risk concomitant use with Opioids	Clonazepam Tablet.docx
3	Colchicine (page 27)	MS400 ANTIGOUT AGENTS	Tablet	Oral	FDA Pregnancy Category C	Colchicine Tablet.docx
3	Dronedaron (page 27)	CV300 ANTIARRHYTHMICS	Tablet	Oral	FDA Pregnancy Category X BW: Risk of death, stroke, and heart failure	Dronedaron Tablet.docx
3	Dutasteride (page 27)	HS900 HORMONES/SYNTHETICS/MODIFIERS	Capsule	Oral	FDA Pregnancy Category X	Dutasteride Capsule.docx
3	Finasteride (page 27)	HS900 HORMONES/SYNTHETICS/MODIFIERS	Tablet	Oral	FDA Pregnancy Category X, Women Pregnant Potential DON'T Handle	Finasteride Tablet.docx
3	Fluconazole (page 27)	AM700 ANTIFUNGALS	Tablet	Oral	FDA Pregnancy Category C	Fluconazole Tablet.docx
3	Fluconazole (page 27)	AM700 ANTIFUNGALS	Bag / Vial	IV Infusion	FDA Pregnancy Category C	Fluconazole Injection.docx
3	Lenvatinib	AN900 ANTINEOPLASTIC OTHER	Capsule	Oral	Avoid Pregnancy During & 2 Weeks after Tx	Lenvatinib Tablet.docx
3	Misoprostol (page 28)	GA309 ANTIULCER AGENTS, OTHER	Tablet	Oral	FDA Pregnancy Category X BW: Abortion< premature birth< birth defects, uterine rupture	Misoprostol.docx
3	Pamidronate (page 29)	HS900 HORMONES/SYNTHETICS/MODIFIERS	Vial	IV Infusion	FDA Pregnancy Category D	Pamidronate.docx
3	Paroxetine (page 29)	CN609 ANTIDEPRESSANTS, OTHER	Tablet	Oral	FDA Pregnancy Category D BW: Suicidality risk	Paroxetine.docx
3	Regorafenib	AN900 ANTINEOPLASTIC OTHER	Tablet	Oral	hepatotoxicity	Regorafenib.docx
3	Ribavirin (page 29)	AM800 ANTIVIRALS	Capsule	Oral	anemia, worsening cardiac disease,	Ribavirin Capsule.docx
3	Temazepam (page 30)	CN302 BENZODIAZEPINE DERIVATIVE	Capsule	Oral	FDA Pregnancy Category X	Temazepam Capsule.docx
3	Testosterone (page 30)	HS100 ANDROGENS / ANABOLICS	Gel / Vial	Topical / IM	FDA Pregnancy Category X	Testosterone.docx
3	Topiramate (page 30)	CN400 ANTICONVULSANTS	Tablet	Oral	FDA Pregnancy Category D	USP 800 Risk Assessments\Topiramate
3	Tretinoin (page 30)	AN900 ANTINEOPLASTIC OTHER	Solution	Topical	Syndrome	Tretinoin.docx
3	Valproate / Valproic acid (page 30)	CN400 ANTICONVULSANTS	Capsule	Oral	FDA Pregnancy Category D BW: Hepatotoxicity, Fetal risk, Pancreatitis	Valproate-Valproic Acid.docx
3	Valproate / Valproic acid (page 30)	CN400 ANTICONVULSANTS	Oral Solution	Oral	FDA Pregnancy Category D BW: Hepatotoxicity, Fetal risk, Pancreatitis	Valproate-Valproic Acid Oral Solution.docx
3	Valproate / Valproic acid (page 30)	CN400 ANTICONVULSANTS	Vial	IV Infusion	FDA Pregnancy Category D BW: Hepatotoxicity, Fetal risk, Pancreatitis	Valproate-Valproic Acid Injection.docx
3	Voriconazole (page 30)	AM700 ANTIFUNGALS	Tablet	Oral	FDA Pregnancy Category D	Voriconazole Oral.docx
3	Voriconazole (page 30)	AM700 ANTIFUNGALS	Vial	IV Infusion	FDA Pregnancy Category D	Voriconazole Injection.docx
3	Warfarin (page 31)	BL110 ANTICOAGULANTS	Tablet	Oral	FDA Pregnancy Category D BW: Bleeding risk	Warfarin.docx
3	Ziprasidone (page 31)	CN709 ANTIPSYCHOTICS, OTHER	Capsule	Oral	FDA Pregnancy category C BW: Increased mortality in elderly patients W/dementia-related psychosis	Ziprasidone Oral.docx
3	Ziprasidone (page 31)	CN709 ANTIPSYCHOTICS, OTHER	Vial	Injection	FDA Pregnancy category C BW: Increased mortality in elderly patients W/dementia-related psychosis	Ziprasidone Injection.docx
3	Zoledronic acid (page 31)	HS900 HORMONES/SYNTHETICS/MODIFIERS	Vial	IV Infusion	FDA Pregnancy Category D	Zoledronic Acid.docx
3	Zonisamide (page 31)	CN400 ANTICONVULSANTS	Capsule	Oral	FDA Pregnancy Category D	Zonisamide.docx